Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ROS-ERS inducer 1
- Development stage
- Preclinical
- Lead developer
- Nanjing University of Chinese Medicine
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
ROS-ERS inducer 1 is a Pt(II)-N-heterocyclic carbene (Pt(II)-NHC) complex derived from 4,5-diarylimidazole. It functions as a type II immunogenic cell death (ICD) inducer by triggering endoplasmic reticulum stress (ERS) and generating reactive oxygen species (ROS), which together lead to the release of damage-associated molecular patterns (DAMPs). This mechanism promotes immunogenic cell death in cancer cells, particularly hepatocellular carcinoma and multiple myeloma, resulting in enhanced antitumor immunity through dendritic cell maturation and T-cell activation. Preclinical studies show that ROS-ERS inducer 1 exhibits significantly higher anticancer activity than cisplatin[1][2][3][4][5][7].
- Other names
- REI
02
Targets
TXNRD2 (Thioredoxin reductase 2)
Beyond the preview
Go deeper on ROS-ERS inducer 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ROS-ERS inducer 1.